New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
August 11, 2014
07:24 EDTBIODBiodel BIOD-531 demonstrates superior glucose control after meals
Biodel announced positive preliminary results from Study 3-152, a Phase 2a clinical trial comparing Biodel's proprietary, concentrated insulin formulation BIOD-531 to Humalog Mix 75/25 and Humulin R U-500 in patients with type 2 diabetes with moderate insulin resistance who use between 50 and 200 units of insulin per day. BIOD-531 was associated with superior glucose control compared to Humalog Mix 75/25 throughout the day of observation. BIOD-531 was also associated with superior glucose control compared to Humulin R U-500. BIOD-531 dosed 20 minutes after the start of the standardized breakfast also resulted in superior glucose control compared to either Humalog Mix 75/25 or Humulin R U-500 dosed prior to the meal. Mean visual analog scores and absolute severity scores were low for all participants, suggesting excellent injection site tolerability.
News For BIOD From The Last 14 Days
Check below for free stories on BIOD the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
There are no results for BIOD

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use